1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy, By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy, By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

  • August 2021
  • 117 pages
  • ID: 6130387
  • Format: PDF
  • TechSci Research

Summary

Table of Contents

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2026

Global Non-Hodgkin Lymphoma (NHL) therapeutics market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% during the forecast period, owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin’s lymphomas (NHL). Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for global Non-Hodgkin Lymphoma (NHL) therapeutics market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.
Non-Hodgkin’s lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body’s immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.
Global Non-Hodgkin Lymphoma (NHL) therapeutics market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region.Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them.In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas.

B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.
Regionally, North America dominated the global Non-Hodgkin Lymphoma (NHL) therapeutics market in 2020 and is further expected to hold its dominance during the forecast period.High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market.

However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.
Major companies operating in global Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc., among others. The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin’s lymphoma therapeutics market. Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.

Years considered for this report:

Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022–2026

Objective of the Study:

• To analyze the historical growth in the market size of global Non-Hodgkin Lymphoma (NHL) Therapeutics market from 2016 to 2020.
• To estimate and forecast the market size of global Non-Hodgkin Lymphoma (NHL) therapeutics market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast global Non-Hodgkin Lymphoma (NHL) Therapeutics market based on type of therapy, cell type, drug type, distribution channel, company and regional distribution from 2021 to 2026 and growth rate until 2026.
• To identify drivers and challenges for global Non-Hodgkin Lymphoma (NHL) therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
• To identify and analyze the profile of leading players operating in the global Non-Hodgkin Lymphoma (NHL) therapeutics market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies which could not be identified due to the limitations of secondary research.
The analyst calculated global Non-Hodgkin Lymphoma (NHL) therapeutics market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by the analyst.

Key Target Audience:

• Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers, companies/partners and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, industry associations, forums and alliances related to Non-Hodgkin Lymphoma (NHL) therapeutics
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as Non-Hodgkin Lymphoma (NHL) Therapeutics manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global Non-Hodgkin Lymphoma (NHL) therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:
o Immunotherapy
o Targeted Therapy
o Chemotherapy
o Stem Cell Transplant
o Others
• Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:
o B-cell Lymphomas
o T-cell Lymphomas
• Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:
o Revlimid
o Rituxan
o Keytruda
o Imbruvica
o Opdivo
o Others
• Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Others
• Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:
o North America
United States
Canada
Mexico
o Europe
Germany
United Kingdom
France
Italy
Spain
o Asia-Pacific
China
Japan
India
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Profit Margin Analysis
• Profit margin analysis in case of direct and indirect sales channel.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on